A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Inclusion Criteria: * 1.Age and gender unlimited; * 2.According to the IMWG2014 standard, diagnosis as multiple myeloma; * 3.According to the MSMART 3.0 standard, it is defined as a high-risk multiple myeloma; * 4.Abnormal plasmocyte BCMA expression positive; * 5.Echocardiography shows the left ventricular ejection score (LVEF) ≥50%; * 6.The subject has no lung activity infection; * 7.Expected life time is more than 3 months; * 8.ECOG score 0-2 score; * 9.Voluntarily participate in the trial and sign the informed consent form. Exclusion Criteria: * 1.Patients with the history of epilepsy or other CNS disease; * 2.Patients with prolonged QT interval time or severe heart disease; * 3.Pregnant or breastfeeding; * 4.Active infection with no cure; * 5.Patients with active hepatitis B or C infection; * 6.Previously treated with any genetic therapy; * 7.The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal; * 8.Serum creatinine \> 2.5mg/dl or ALT / AST \> 3 times ULN or bilirubin \> 2.0mg/dl; * 9.Those who suffer from other uncontrolled diseases are not suitable to join the study; * 10.HIV infection; * 11.Any situation that the researchers believe may increase the risk of patients or interfere with the test results.